http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2299727-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8723d388c255187bc4fb506dd8c00816 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce89b87da31cd879b94cf097d6c938fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb0e244981b0505b8f18c0f1b4db248 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feac6e8bb77cc82ac6f8e98532c3d77b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_111e354f07c8c14dd5592e65d407c9b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69467cb9eccd644eca7f212d1411890e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a825b2d620d17a9a6adbbecc8ee9e908 |
| publicationDate | 2007-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2299727-C2 |
| titleOfInvention | Method for complex treatment of lymphogranulomatosis |
| abstract | FIELD: medicine, oncology. n SUBSTANCE: method involves carrying out polychemotherapy by 4 courses with 3-week breaks. The first and the third course show duration for 15 days, and the second and the fourth courses - for 8 days each. Polychemotherapy is carried out by the following schedule: in the first and third course belustin is administrated in the first day, etoposide is administrated in the first, second and third days. Doxorubicin is administrated in the first and fifteen days. Bleomycin, viblastin, dacarbazine are administrated in the fifteen day. The second and fourth courses involve administration of doxorubicin, bleomycin, vinblastin and dacarbazine in the first and eighth days. Method provides reducing time required for the complex treatment of lymphogranulomatosis based on decreasing number of cycles of polychemotherapy and in improving two-year indices of relapse-free viability. Invention can be used in the complex treatment of lymphogranulomatosis. n EFFECT: improved method of treatment. n 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2462192-C1 |
| priorityDate | 2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.